T2Bacteria® RUO Panel Results Show Detection of Clinically Important Infections Missed by Blood Culture
At the Association for Molecular Pathology (AMP) 2017 conference, Chiagozie Ononye, M.D. of Northwestern University’s Feinberg School of Medicine presented on her early experience with the T2Bacteria RUO Panel when testing clinical specimens as compared to paired blood culture results.
Watch our presentation on the T2Bacteria RUO at the 2017 Association of Molecular Pathology conference.
Tom Lowery, Ph.D., chief scientific officer of T2 Biosystems, presented: The Impact of Direct from Whole Blood Diagnostics on the Management of Bloodstream Infections.”
JOIN THE MAILING LIST!
T2 BIOSYSTEMS OVERVIEW
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.